Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBT (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed EBT for 13 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 3.94% year-over-year to -$1.0 million, compared with a TTM value of -$6.5 million through Sep 2025, down 58.28%, and an annual FY2024 reading of -$5.4 million, down 30.6% over the prior year.
  • EBT was -$1.0 million for Q3 2025 at Sunshine Biopharma, up from -$2.0 million in the prior quarter.
  • Across five years, EBT topped out at $667116.0 in Q4 2021 and bottomed at -$23.3 million in Q4 2022.
  • Average EBT over 5 years is -$2.8 million, with a median of -$1.2 million recorded in 2022.
  • Peak annual rise in EBT hit 161.55% in 2021, while the deepest fall reached 6461.84% in 2021.
  • Year by year, EBT stood at $667116.0 in 2021, then crashed by 3589.5% to -$23.3 million in 2022, then skyrocketed by 95.58% to -$1.0 million in 2023, then plummeted by 122.09% to -$2.3 million in 2024, then surged by 55.34% to -$1.0 million in 2025.
  • Business Quant data shows EBT for SBFM at -$1.0 million in Q3 2025, -$2.0 million in Q2 2025, and -$1.2 million in Q1 2025.